Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?

We report a case of Guillain-Barré syndrome (GBS) following the first dose of Oxford/AstraZeneca COVID-19 vaccine with papilledema as atypical onset. As the COVID-19 vaccination campaign progresses worldwide, GBSs vaccine-related have been increasingly reported. After reviewing the available literat...

Descripción completa

Detalles Bibliográficos
Autores principales: Introna, Alessandro, Caputo, Francesca, Santoro, Carlo, Guerra, Tommaso, Ucci, Maria, Mezzapesa, Domenico Maria, Trojano, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360997/
https://www.ncbi.nlm.nih.gov/pubmed/34418708
http://dx.doi.org/10.1016/j.clineuro.2021.106887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360997/
https://www.ncbi.nlm.nih.gov/pubmed/34418708
http://dx.doi.org/10.1016/j.clineuro.2021.106887

Ejemplares similares